Lilly clearly has an abundance of growth drivers -- and the list includes more than Mounjaro, Zepbound, and the six drugs ...

Demand for Eli Lilly’s Zepbound and Mounjaro has outstripped supply over the last year, forcing the company to invest heavily ...

With a market capitalization of over $800 billion, Eli Lilly (NYSE: LLY) is the largest pharmaceutical company in the world.

Eli Lilly and rival Novo Nordisk have been battling the emerging industry making copies of their top-selling diabetes and weight-loss drugs, a situation without modern precedent. It started in ...

In fact, demand has been so high that it's been surpassing supply, forcing Lilly and rival Novo Nordisk to invest in ...

The drugs have also shown promising capabilities of reducing the risk of severe cardiac issues and even reduce the risk of diabetes progression. Eli Lilly shares were up almost 2% to $966.93 as of ...

About 86% of commercial healthcare plans cover the cost of obesity drugs ... often used to treat diabetes have soared in popularity for weight loss use. Eli Lilly raised its sales forecast ...

Eli Lilly is reducing the cost of certain weight drugs like Zepbound due to a growing demand. Single-dose vials will cost consumers 50% less than GLP-1 medicines used for obesity. The ...

Eli Lilly will invest $1.8 billion to boost manufacturing for its newly approved Alzheimer's drug and highly popular weight loss and diabetes treatments, among other medicines, in Ireland.